| NBMBX | PMBJX | NBMBX / PMBJX | |
| Total Expense Ratio | 1.18 | 0.76 | 155% |
| Annual Report Gross Expense Ratio | 1.18 | 0.76 | 155% |
| Fund Existence | 30 years | 25 years | - |
| Gain YTD | 4.101 | -0.745 | -551% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 1000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.23B | 23.2B | 10% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | -18.65 | -10.41 | 179% |
| Returns for 3 years | 7.83 | 20.17 | 39% |
| Returns for 5 years | -32.05 | -1.32 | 2,431% |
| Returns for 10 years | 12.40 | 79.67 | 16% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPXX | 19.08 | 0.09 | +0.47% |
| Nuveen S&P 500 Dynamic Overwrite Fund | |||
| FBDC | 17.67 | N/A | -0.01% |
| FT Confluence BDC & SpecialtyFinacIncETF | |||
| CALI | 50.38 | -0.01 | -0.03% |
| iShares Short-Term CA Muni Act ETF | |||
| WEA | 10.43 | -0.05 | -0.48% |
| Western Asset Premier | |||
| BIS | 10.82 | -0.30 | -2.70% |
| ProShares UltraShort Nasdaq Biotech | |||